What's Hot

View all perspectives
      A randomised clinical trial show improvements in clinical outcomes CDAI, VAS for both the ITIS diet and the Med diet. Ba

      Dr. Antoni Chan

      1 year ago
      A randomised clinical trial show improvements in clinical outcomes CDAI, VAS for both the ITIS diet and the Med diet. Baseline differences in the microbiome between responders and non-responders were seen. Sala Climent M, Abst#2124 #ACR23 @RheumNow https://t.co/tiyNcV7cmD https://t.co/EEP4zrwjXs
      Abstract 2583 at #ACR23

      👉Possible predictive model of at risk of RA patients with ACPA positivity based on baseline

      Meral K. El Ramahi, MD MeralElRamahiMD

      1 year ago
      Abstract 2583 at #ACR23 👉Possible predictive model of at risk of RA patients with ACPA positivity based on baseline levels of peripheral blood lymphocyte sub-populations: ⭐️High % of B cell and low % of NK cells increase the probability of developing arthritis in ACPA + pts… https://t.co/3KEOI4eul0 https://t.co/irX6InWMbl
      Large French study on infection risk of PsA biologics
      12k pts over 6 years
      When compared to Humira, only Enbrel and Ste

      Robert B Chao, MD

      1 year ago
      Large French study on infection risk of PsA biologics 12k pts over 6 years When compared to Humira, only Enbrel and Stelara had lower infection risk Concurrent steroid use associated with increased infection 1.85HR @RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
      Saliclick: minor salivary gland biopsy was a safe and rapid procedure for the diagnosis in Sjögren’s Syndrome without

      Dr. Antoni Chan

      1 year ago
      Saliclick: minor salivary gland biopsy was a safe and rapid procedure for the diagnosis in Sjögren’s Syndrome without observed numbness occurring, focal lymphocytic sialadenitis in 20%, with a focus score >1 for 62%. Hugle T, Abst#2190 #ACR23 @RheumNow https://t.co/VYKdQw2YlC https://t.co/dWLWj2AdkI
      Trajectory of FVC in Systemic sclerosis associated ILD in open label SENSCIS study
      Decline in FVC over 52 weeks decreas

      Robert B Chao, MD

      1 year ago
      Trajectory of FVC in Systemic sclerosis associated ILD in open label SENSCIS study Decline in FVC over 52 weeks decreased by 57% on nintedanib But am I also just seeing a study FVC decline even with nintedanib? @RheumNow #ACR23 Abs#2594 https://t.co/3h4mhm0ceU
      A model for prediction of progression to RA

      Factors asso w/ progression
      -ACPAs
      -High % B cells
      -Low % NK cells

      Only in

      Aurelie Najm

      1 year ago
      A model for prediction of progression to RA Factors asso w/ progression -ACPAs -High % B cells -Low % NK cells Only in ACPA+ individuals Low ACPA titers, High % NK cells and Low B cells = 76% non progressors @RheumNow #ACR23 ABST2583 https://t.co/vNIwyrOJtJ
      AR882 a novel and selective URAT1 inhibitor is a safe, efficacious sUA lowering, tophus resolution and with a 68% decrea

      Dr. Antoni Chan

      1 year ago
      AR882 a novel and selective URAT1 inhibitor is a safe, efficacious sUA lowering, tophus resolution and with a 68% decrease in total urate crystal volume of the feet and ankles after AR882 75 mg once daily for 6 months. Keenan R, Abst#L15 #ACR23 @RheumNow https://t.co/gMCcSI1v9W https://t.co/lk3XQCaw0A
      ⭐️Further Assessment of a patient with rash c/w leukocytoclastic vasculitis:

      👉History:
      ⏺️Timing, onset, pr

      Meral K. El Ramahi, MD MeralElRamahiMD

      1 year ago
      ⭐️Further Assessment of a patient with rash c/w leukocytoclastic vasculitis: 👉History: ⏺️Timing, onset, progression? ⏺️Recent infectious for infectious symptoms? ⏺️Recent/new meds? ⏺️Hx of cancer? 👉Laboratory assessment for ALL: ⏺️CBC w/ diff ⏺️CMP (w/ interest in Cr,… https://t.co/tVqz6XDXt2 https://t.co/LqZpx5j0Bp
      1st Large real world observational head to head study on tx of Systemic sclerosis - ILD

      No difference in treatment effe

      Robert B Chao, MD

      1 year ago
      1st Large real world observational head to head study on tx of Systemic sclerosis - ILD No difference in treatment effectiveness of FVC change between tocilizumab, rituximab, mycophenolate and cyclophosphamide! @RheumNow #ACR23 Abs#2596 #ACRBest https://t.co/GaSnZSCcnZ
      Fecal transplant for treatment of GI complications of systemic sclerosis?

      No change in those who received transplant..

      Robert B Chao, MD

      1 year ago
      Fecal transplant for treatment of GI complications of systemic sclerosis? No change in those who received transplant... Overall procedure safe @RheumNow #ACR23 Abs#2597 https://t.co/TEdeGHuzpi
      JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even i

      Dr. Antoni Chan

      1 year ago
      JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even in refractory cases. Evolution of FVC and DLCO remained stable in first 12 months. Serrano-Combarro A, Abst#2174 #ACR23 @RheumNow https://t.co/82mMn5oh15 https://t.co/e7wrgmTOTA
      Fecal microbiota - can it predict development of RA?

      Sadly, no. Despite promising mouse work. Despite relative control

      David Liew drdavidliew

      1 year ago
      Fecal microbiota - can it predict development of RA? Sadly, no. Despite promising mouse work. Despite relative control of exposure & genetic enrichment incl SE. Not even Prevotella. Maybe if you compare the most extreme cases but it’s not all the gut. #ACR23 ABST2584 @RheumNow https://t.co/VgDZaH9kvo
      Pre-clinical RA trials roundup, but also:

      Great use (and acknowledgment) of RheumNow slide in the abstract background.

      David Liew drdavidliew

      1 year ago
      Pre-clinical RA trials roundup, but also: Great use (and acknowledgment) of RheumNow slide in the abstract background. Glad to see it being helpful there! #ACR23 ABST2585 @RheumNow https://t.co/sK6bDJrYjV
      Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progressio

      Dr. Antoni Chan

      1 year ago
      Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA
      Continued interest on CAR-T cells in systemic sclerosis!

      6 mo f/up data on 3 pts who received CAR-T cell treatment - st

      Robert B Chao, MD

      1 year ago
      Continued interest on CAR-T cells in systemic sclerosis! 6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall Skin findings improved in all 3 pts Previous finger ulcerations resolved Lung function stable in 2 pts, improved in 1 @RheumNow #ACR23 Abs#2598

      Podcasts

      • ACR24 - IL - 17
      • ACR24 - JAK TYK2
      • ACR24 - LUPUS

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.